ANI Pharmaceuticals (ANIP): Four Filters, One Drug (2026)

Today's pick passes every hard screening criterion. ANI Pharmaceuticals (NASDAQ: ANIP) clears all four mandatory filters — market cap below $10B, TTM revenue growth above 30%, PEG below 1, and positive operating cash flow. As of May 19, 2026, the stock sits at $80.32, roughly 19% below its 52-week high of $99.50.

Screening verdict

Hard filter	Threshold	ANIP result	Status
Market cap	< $10B	$1.83B 1	✅ Pass
TTM revenue growth	> 30%	37.04% 2	✅ Pass
PEG ratio	< 1	0.47 (non-GAAP basis) 1	✅ Pass
Operating cash flow	Positive	+$208.61M TTM 1	✅ Pass

PEG calculation note: GAAP TTM earnings are positive ($3.91 diluted EPS 1), but the prior-year TTM period included a GAAP loss due to one-time acquisition costs from the Alimera Sciences deal in September 2025 — making the GAAP-to-GAAP growth rate technically undefined. On non-GAAP EPS, the trailing twelve months came in at $8.22 vs. $5.75 in the prior period, a 43% growth rate. At the current non-GAAP trailing P/E, that yields a PEG of 0.47 — well inside the threshold.

What ANI Pharmaceuticals does

ANI Pharmaceuticals is a specialty and generic pharmaceutical company headquartered in Baudette, Minnesota. Its business operates across three segments: Rare Disease (branded specialty drugs), Generics, and Established Brands.

The company's engine is Cortrophin Gel — an adrenocorticotropic hormone (ACTH) gel indicated for multiple inflammatory and autoimmune conditions including acute exacerbations of multiple sclerosis, nephrotic syndrome, and infantile spasms. ANI re-launched Cortrophin Gel commercially in 2022 after winning an FDA approval to reintroduce the product at scale. What had been a dormant asset became the company's primary growth driver.

ANI expanded its Rare Disease footprint in September 2025 by completing the acquisition of Alimera Sciences, which added ILUVIEN (a long-acting intravitreal implant for diabetic macular edema) and YUTIQ (another sustained-release eye implant) to the portfolio 3. Rare Disease is guided to represent approximately 60% of total 2026 revenue 2.

The Generics segment — manufacturing and distributing off-patent pharmaceutical products — provides a stable, cash-generative base that partially offsets industry-wide generic pricing pressure.

Financial performance

Q1 2026 was the twelfth consecutive quarter of revenue growth. Revenue of $237.5M grew 20.5% YoY versus Q1 2025's $197.1M 2.

Loading chart…

Sources: 2 4

The Q1 2026 earnings beat was the most notable part of the quarter. The analyst consensus expected non-GAAP EPS of $1.23; ANIP delivered $2.05 — a 66.7% beat 5. Gross margin expanded to 60.8% in Q1 2026 from approximately 58% in the prior-year period 5. Adjusted non-GAAP EBITDA came in at $63.0M 2.

CEO Nikhil Lalwani on the Q1 results: "We delivered a strong first quarter, generating $237.5 million in revenue and $63.0 million in adjusted non-GAAP EBITDA, with solid performance across all business units." 2

Following Q1, management raised full-year 2026 guidance by $25M at the midpoint 3:

Total revenue: $1,080M–$1,140M (implying 17–23% full-year growth over 2025)
Adjusted non-GAAP EBITDA: $285M–$300M
Adjusted non-GAAP EPS: $9.19–$9.69
Cortrophin Gel revenue: $540M–$575M (reaffirmed)

Balance sheet: $311.2M cash as of Q1 2026 2, $630.2M total debt 1, yielding net debt of ~$319M. Net debt/EBITDA is approximately 1.54x on $197M trailing EBITDA — manageable given $208.6M TTM OCF. Current ratio is 3.12 1.

Valuation

ANIP — valuation as of May 19, 2026

Stock price $80.32; market cap $1.83B

Trailing P/E	20.5x
Forward P/E (FY2026 guidance midpoint)	8.5x
Price/Sales (TTM)	1.98x
EV/EBITDA	10.79x
Price/FCF	13.02x
Non-GAAP PEG	0.47

Loading stats card…

Sources: 1

The forward P/E of 8.5x is the figure that anchors the investment case. It uses the FY2026 non-GAAP EPS guidance midpoint of $9.44 and the current price of $80.32. For context, AMPH (Amphastar Pharmaceuticals, which develops and manufactures injectable and inhalation generics at $2.89B market cap) trades at a trailing P/E of 10.74x on roughly $720.5M revenue 1. SUPN (Supernus Pharmaceuticals, a CNS specialty pharma company at $1.76B cap with $776.8M revenue) currently shows a negative net income line 1. Neither peer is growing revenue at 37%.

Why does the forward multiple look so compressed? Two explanations are plausible and not mutually exclusive. First, Cortrophin Gel's revenue trajectory is not yet confirmed as a multi-year durable growth driver at the $540M–$575M guidance level — the drug's current competitive moat (it has no direct ACTH competitor at scale) could attract a generic challenger or face formulary pressure. Second, the 18.98% short float 1 signals that a meaningful portion of institutional investors is positioned for the stock to decline, likely reflecting concentration risk and insider selling (discussed below).

Analyst consensus: 12 analysts cover ANIP. The median 12-month price target is $110, with a range of $90 to $124 5, implying roughly 37% upside from $80.32. Wall Street Zen upgraded ANIP to Strong Buy on May 9, 2026, following the Q1 earnings beat 6. Analyst price targets carry systematic optimism bias; the current stock price at roughly a 27% discount to the average target of $107.33 is a data point, not a verdict.

Growth catalysts

Cortrophin Gel is the primary driver — and it is still accelerating. Q1 2026 Cortrophin Gel revenue was $75.1M, up 42% YoY 2. Full-year 2025 Cortrophin revenue was $348M. The midpoint of the 2026 guidance range ($557.5M) implies roughly 60% growth YoY for the full year — meaning Q1's pace would need to hold or slightly decelerate. CEO Lalwani stated: "Based on our performance, we are raising our financial guidance which reflects more than $1.0 billion in revenue in 2026, with Rare Disease representing approximately 60% of total revenue." 2

Acute gouty arthritis expansion is the next indication. ANI is seeking FDA approval for a supplemental NDA (sNDA) to expand Cortrophin Gel's label to include acute gouty arthritis. The company says the commercial team for this expansion is "mostly hired" 5. If approved, this adds a new patient population to the drug without requiring a new manufacturing or distribution infrastructure build.

ILUVIEN integration adds a second revenue pillar. ILUVIEN (intravitreal fluocinolone acetonide implant for diabetic macular edema) contributed $19.3M in Q1 2026 2 and is still in early integration. ANI is cross-selling into the ophthalmology channel via the same rare disease commercial infrastructure.

$100M share repurchase program adds a floor. The board authorized a $100M buyback alongside Q1 results 3. At a $1.83B market cap, $100M represents roughly 5.5% of outstanding shares if executed near current prices. This is a signal that the board views the stock as undervalued relative to cash generation — though the buyback authorization and the insider selling pattern pull in opposite directions.

Generics provides ballast. The Generics segment posted $105.4M in Q1 2026 2, a steady, cash-generative base that funds Rare Disease commercial investment while the branded drug ramps.

Risks and what to watch

Cortrophin Gel concentration is the single biggest variable. At the FY2026 guidance midpoint, Cortrophin accounts for roughly 50% of total projected company revenue ($557.5M out of $1.11B midpoint). A competitor ACTH entry, a formulary restriction by a major pharmacy benefit manager (PBM), or a payer coverage shift would directly impact roughly half of projected revenue. ANI has enjoyed a de facto monopoly position in ACTH therapy since Mallinckrodt's Acthar Gel ran into legal and financial trouble — but that absence of direct competition is a circumstance, not a structural moat. There is no publicly available data on generic ACTH development timelines.

Insider selling with no offsetting purchases is a consistent pattern. Over the past six months, company insiders recorded 17 open-market sales and zero purchases 1. CEO Nikhil Lalwani sold 55,000 shares for approximately $4.2M at $77.57 in March 2026 7. Director Patrick D. Walsh sold 13,973 shares in April 2026 8. Many insider sales are pre-scheduled under 10b5-1 plans (SEC-approved programs that allow executives to sell shares on a fixed schedule, insulating them from insider trading claims), which limits how much can be inferred from any individual transaction — but one-directional selling over a six-month window with no insider purchases is a data point that warrants attention. Insider ownership stands at 6.89% of shares outstanding 1.

Short interest of 18.98% is unusually high for this market cap tier. The short ratio is 10.78 days to cover 1, meaning a short squeeze is plausible if positive catalysts emerge — but the elevated short float also signals that institutional investors who have done detailed work on the name hold a negative view. That is worth understanding before taking a position.

Generics pricing pressure is secular, not cyclical. The branded specialty pipeline is where ANIP's growth story lives, but the Generics segment ($105.4M in Q1 2026) faces ongoing industry-wide price erosion. This creates a structural drag that management has to continuously offset with branded growth.

Debt service is not a near-term concern but bears monitoring. Net debt of approximately $319M at 1.54x EBITDA is moderate given $208.6M TTM OCF. However, the Alimera acquisition was funded partly with debt, and if Cortrophin growth decelerates sharply, deleveraging capacity narrows quickly.

Price action and upcoming catalysts

At $80.32 (May 19 close), ANIP is up approximately 1.75% year-to-date from a December 31, 2025 close of $78.94 1. The 52-week range is $56.71–$99.50. The stock has a beta of 0.46, meaning it has historically moved at roughly half the volatility of the S&P 500.

Key upcoming catalysts:

Q2 2026 earnings — expected around August 2026. The consensus estimate is $1.95 non-GAAP EPS 5 vs. the $2.05 that cleared in Q1. A second consecutive beat would compress the short thesis materially.
Cortrophin acute gouty arthritis sNDA — no specific FDA action date is publicly disclosed. Approval would expand the addressable patient population for the drug without a new commercial infrastructure build.
Alimera integration milestones — cross-selling ILUVIEN into the ophthalmology channel is still early; quarterly ILUVIEN revenue trend is the observable proxy.

Institutional ownership is 110.16% of the float (implying significant short-selling by institutions is included in the calculation) 1. Major holders include BlackRock and Vanguard Group 1.

Screening data as of May 19–20, 2026. All financial figures sourced from company press releases and Yahoo Finance. This article is for research informational purposes only and does not constitute investment advice.